title: Mirtazapine decreases the pain feeling in healthy participants.
abstract: OBJECTIVE
  The treatment of neuropathic pain is mainly based on antiepileptics, tricyclic antidepressants, and opiates. These drugs have important side effects disturbing the patient's quality of life. Mirtazapine (MTZ) is a new and well-tolerated tricyclic antidepressants with both monoaminergic and opioid properties that might favorably influence pain. The aim of this study was to assess whether MTZ can reduce the pain induced by a standardized stimulus presented to healthy human participants. The nociceptive flexion reflex (NFR) to an electric stimulus was chosen to determine the pain threshold.
  
  
  METHODS
  The effect of MTZ compared to placebo was assessed on 10 healthy participants in a double-blinded cross-over design. The NFR was measured the day after a single oral dose of drug (30 mg) or placebo.
  
  
  RESULTS
  A significant increase in upper limb (+29%, P=0.006) NFR threshold was observed.
  
  
  CONCLUSIONS
  MTZ increases the pain tolerance in healthy participants. The potential benefit of this effect on pain should be investigated more thoroughly in chronic neuropathic pain patients. The NFR might serve as an additional tool for the monitoring of these patients.
authors.affiliation: Service de réadaptation neurologique Clinique romande de réadaptation SuvaCare, Sion, Switzerland. pierre.arnold@crr-suva.ch
authors.forename: Pierre
authors.initials: P
authors.lastname: Arnold
authors.forename: Philippe
authors.initials: P
authors.lastname: Vuadens
authors.forename: Thierry
authors.initials: T
authors.lastname: Kuntzer
authors.forename: Charles
authors.initials: C
authors.lastname: Gobelet
authors.forename: Olivier
authors.initials: O
authors.lastname: Deriaz
mesh_terms: D000328:Adult; D000700:Analgesics / Q000008:administration & dosage* / Q000009:adverse effects; D000929:Antidepressive Agents, Tricyclic / Q000008:administration & dosage* / Q000009:adverse effects; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004558:Electric Stimulation / Q000009:adverse effects; D005260:Female; D006801:Humans; D007866:Leg / Q000294:innervation / Q000503:physiopathology; D008297:Male; D008803:Mianserin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D008875:Middle Aged; D000078785:Mirtazapine; D009437:Neuralgia / Q000188:drug therapy* / Q000503:physiopathology; D009619:Nociceptors / Q000187:drug effects / Q000502:physiology; D010147:Pain Measurement / Q000187:drug effects; D017288:Pain Threshold / Q000187:drug effects / Q000502:physiology; D010525:Peripheral Nerves / Q000187:drug effects / Q000503:physiopathology; D010523:Peripheral Nervous System Diseases / Q000188:drug therapy* / Q000503:physiopathology; D015990:Placebo Effect; D011930:Reaction Time / Q000187:drug effects / Q000502:physiology; D012018:Reflex / Q000187:drug effects / Q000502:physiology; D016896:Treatment Outcome
chemical_list: D000700:Analgesics; D000929:Antidepressive Agents, Tricyclic; D008803:Mianserin; D000078785:Mirtazapine